Elevance Health just posted its Q3 2026 scorecard and the stock has shrugged off any hesitation. Shares are up 2.6% today to about US$445 even as earnings per share of US$6.30 sit below the prior quarter and net income is US$1.37b on more than US$51b of revenue.
That is the sentiment clash investors need to watch. Short term traders are cheering the raised 2026 adjusted earnings guidance and the promise of at least 12% adjusted EPS growth in 2027, while the actual quarterly profit squeeze tells a tighter story underneath.
Love Elevance Health's scale and raised guidance but uneasy about the profit squeeze showing up in this quarter? Screen for insurers and healthcare stocks that pair resilient earnings with stronger balance sheets in our list of solid balance sheet and fundamentals stocks (26 results) .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$51,429m vs. US$50,711m (top line broadly steady with a modest year on year uplift)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025):US$1,365m vs. US$1,189m (profit level higher year on year, while the current quarter sits below recent peaks cited earlier)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$6.30 vs. US$5.32 (per share earnings higher than the prior year quarter, with management's adjusted EPS figure discussed in the call commentary)
-
Trailing 12-Month Net Income Margin (Q3 2026 vs. prior year):2.5% vs. 2.8% (margin compression at the enterprise level alongside higher revenue and raised adjusted EPS guidance)
Guidance jumped after nonoperating gains, but Carelon did the grinding. Ask Charlie what makes Carelon Elevance Health's real earnings engine .
Elevance Health's Platform Ambition Meets Early Proof Points
Elevance Health's bullish story hangs on whether its tech and Carelon engines really tighten cost control rather than just sounding impressive.
"HealthOS and Sydney Health are already shortening the time it takes Elevance Health to spot emerging cost patterns, and wider use of these tools to automate prior authorization and tighten billing integrity could shift earnings quality by reducing surprise movements in the benefit expense ratio and supporting more predictable net margins."
The Q3 benefit expense ratio of 90.6% and raised adjusted EPS guidance to at least US$29 suggest cost trends are currently contained while CarelonRx delivered about 10.8% operating gains and a 5.3% margin. That combination points to early traction, although the trailing 12 month net margin of 2.5% still caps how far this thesis has progressed.
Government And Membership Risks Still Shadow Elevance Health
The bearish script focuses on whether government exposure and mix shifts quietly erode the very earnings visibility the platform story promises.
"Medical membership fell to 44.9 million by Q2 2026 due to fee based commercial transitions and attrition in individual ACA and Medicaid lines. If similar membership losses or a further shift toward lower premium products continue, Elevance Health could see softer premium and fee based revenue that makes its current earnings and cash flow guidance more difficult to sustain."
Q3 tells a more mixed story. Medicaid, Medicare Advantage and Individual lines contributed to outperformance and guidance rose, which argues against immediate pressure from membership and product mix. Yet the trailing margin compression from 2.8% to 2.5% shows the drag risk has not fully cleared.
The price and this Narrative do not agree. → Uncover what this Narrative says Elevance Health is actually worth .
Hunt For Quiet Fundamental Disconnects
Elevance Health's guidance shift and margin squeeze show sentiment moving away from reported fundamentals. The real opportunity could sit in stocks that look mispriced before expectations catch up.
-
Company 1 - 40% below our estimate - targets higher run rate margins by scaling new manufacturing capacity into premium film, installation and dealership channels.
-
Company 2 - 49% below our estimate - leans on a record backlog of large fixed price infrastructure and military projects requiring disciplined bidding and cleaner contract terms.
-
Company 3 - 23% below our estimate - expands manufacturing capacity for AI heavy data center optics and higher value photonics while reducing supply bottlenecks and customer concentration.
That is three of the list. See every one of the 29 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ELV .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
